MMMajid Taati Moghadam

Majid Taati Moghadam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Majid Taati Moghadam has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Samane Mohebi

    Department of Bacteriology and Virology School of Medicine Shiraz University of Medical Sciences Shiraz Iran

    4 shared publications
  • Aref Shariati

    Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran

    3 shared publications
  • Amin Sadeghi Dousari

    Stem Cells and Regenerative Medicine Innovation Center, Kerman University of Medical Sciences, Kerman, Iran

    2 shared publications
  • Hadi Sedigh Ebrahim-Saraie

    Department of Microbiology, Virology and Microbial Toxins, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran

    2 shared publications
  • Mahin Naderifar

    School of Medicine, Zabol University of Medical Sciences, Zabol, Iran

    2 shared publications
  • Majid Reza Akbarizadeh

    School of Medicine, Zabol University of Medical Sciences, Zabol, Iran

    2 shared publications

Latest Publications

  • IgY-Based Immunotherapy Against MDR/XDR/PDR Bacterial Infections: Mechanisms and Experimental Evidence From In Vitro and In Vivo Studies

    byĀ Narjes Aghajani, Meysam Hasannejad-Bibalan, Hadi Sedigh Ebrahim-Saraie, Majid Taati Moghadam

    Antimicrobial resistance (AMR) has emerged as one of the greatest threats to global public health, largely driven by the rapid dissemination of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacterial pathogens. The limited antibacterial pipeline, together with the declining effectiveness of conventional antibiotics, highlights the urgent need for alternative therapeutic strategies. Among emerging immunotherapeutic approaches, immunoglobulin Y (IgY), the principal antibody found in egg yolk, has attracted increasing attention because of its high specificity, favorable safety profile, ethical and scalable production, and low propensity to promote antimicrobial resistance. Experimental evidence consistently demonstrates that pathogen-specific IgY exhibits potent antibacterial activity against priority MDR pathogens, including Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Salmonella enterica. Across multiple in vitro and animal studies, IgY reduced bacterial burden, inhibited biofilm formation and bacterial motility, enhanced opsonophagocytic clearance, attenuated inflammatory responses, improved survival, and frequently restored or potentiated the activity of conventional antibiotics. Recent advances in inhalable formulations, nanoparticle-based delivery systems, and combination therapies further expand the translational potential of IgY for managing difficult-to-treat bacterial infections. Therefore, current evidence supports IgY as a promising immunotherapeutic strategy that may complement conventional antimicrobial therapy and, in selected settings, potentially serve as an alternative to antibiotics. Although encouraging preclinical findings have accumulated, additional well-designed clinical trials, standardized manufacturing protocols, and optimized delivery platforms are essential to define the clinical settings in which IgY can safely and effectively be used alone or alongside conventional antimicrobial therapy.

  • Open Access

    A Comprehensive Study of Bidirectional Interactions Between the Human Microbiome and Blood Malignancies and Hematologic Conditions: Focus on Novel Therapeutic Strategies

    byĀ Alireza Molajafari, Hadi Sedigh Ebrahim‐Saraie, Majid Taati Moghadam, Meysam Hasannejad‐Bibalan

    Background: The human microbiota plays a key role in maintaining host homeostasis by regulating immune responses, metabolism, and hematopoiesis. Microbial dysbiosis has been increasingly associated with immune dysfunction, inflammation, and bone marrow abnormalities that may contribute to hematological diseases. This review summarizes current evidence on the role of the microbiota in normal hematopoiesis and its potential involvement in benign and malignant hematological disorders. Methods: A narrative literature review was conducted through comprehensive searches of major scientific databases without time restrictions using the keywords Microbiome, Dysbiosis, Hematopoiesis, Anemia, Immune Thrombocytopenia, Congenital Neutropenia, Thrombosis, Lymphoma, Leukemia, and Multiple Myeloma. Relevant experimental, clinical, and review articles were screened and synthesized. Results: Available evidence suggests that the microbiota may influence hematopoietic stem cell function, immune cell development, and hematopoietic homeostasis. Microbial dysbiosis has been proposed to be associated with benign hematological disorders, including anemia, immune thrombocytopenia, congenital neutropenia, and thrombosis, as well as hematological malignancies such as leukemia, lymphoma, and multiple myeloma. Certain bacterial and viral infections may also influence disease progression and therapeutic responses. Microbiota‐targeted interventions, including probiotics, prebiotics, dietary interventions, fecal microbiota transplantation, and other microbiome‐based therapies, have shown potential as adjunctive therapeutic strategies. Conclusions: Current evidence suggests that microbiota dysbiosis may contribute to the pathogenesis of various hematological disorders. A better understanding of host–microbiota interactions may support the development of novel biomarkers and microbiota‐based therapeutic approaches, although further clinical studies are required to confirm their efficacy and safety.

  • Open Access

    Ramadan intermittent fasting and the gut microbiome: modulation of diversity and implications for metabolic health

    byĀ Shahla Shahbazi, Soheila Aminzadeh, Majid Taati Moghadam, Sajad Rajabi, Seyedeh Shadi Vaziri, Mosayeb Rostamian

    Ramadan fasting (RF), a culturally embedded form of time-restricted eating, involves daily abstinence from food and drink from dawn to sunset and provides a real-world human model to examine the potential impact of intermittent fasting on the gut microbiome and metabolic health. This review synthesizes evidence from human studies, predominantly observational in design, to evaluate the associations between RF, microbial composition and diversity, and metabolic outcomes. Current evidence suggests that RF may be associated with changes in gut microbial richness and community structure, including reported increases in taxa such as Akkermansia muciniphila , Faecalibacterium prausnitzii, Roseburia , and Bacteroides , many of which are linked to short-chain fatty acid (SCFA) production and intestinal barrier function. However, findings across studies are not entirely consistent, particularly with respect to microbial taxa abundance and SCFA levels. Observational studies also report concurrent changes in anthropometric and metabolic parameters, including body weight, lipid profiles, glycemic markers, and inflammatory indices, although these associations may be influenced by confounding factors such as dietary composition, lifestyle changes, and weight loss during Ramadan. Proposed mechanisms include alterations in feeding–fasting rhythms and microbiota-related pathways such as bile acid metabolism and gut barrier function; however, these mechanisms are largely inferred from related experimental models and should be considered hypothesis-generating in the context of RF. Therefore, while RF represents a relevant ecological model for studying time-restricted eating in humans, the current evidence remains limited by small sample sizes, interindividual variability, and methodological heterogeneity. Further well-controlled, longitudinal, and multi-omics studies are required to clarify causal relationships and determine the extent to which RF-associated microbial changes contribute to metabolic health.


  • Can Phage Therapy Revolutionize Treatment of Pan-Drug-Resistant Infections in Clinical Settings?

    byĀ Majid Taati Moghadam, Hadi Sedigh Ebrahim-Saraie, Arezoo Msc Barani, Meysam Hasannejad-Bibalan


  • Open Access

    Ribotyping for Accurate Identification of Infectious Bacteria in Animal‐Derived Foods and Laboratory Samples: Implications for Human Health

    byĀ Zahra Pourramezan Seyedi, Baharak Mirzavand, Majid Taati Moghadam, Mohammad Taghi Ashoobi, Jamile Nowsani

    Ribotyping is a molecular typing approach based on ribosomal RNA (rRNA) gene sequences for the identification and characterization of bacterial strains. This review aims to evaluate the effectiveness of ribotyping in the identification of infectious bacteria in animal‐derived foods and veterinary samples. A narrative literature review was conducted using major scientific databases, including PubMed, Scopus, Google Scholar, and Web of Science, covering studies published to 2025. Relevant articles were selected based on their focus on ribotyping methodologies (e.g., RFLP‐, PCR‐, and automated ribotyping) and their applications in food safety, veterinary microbiology, and zoonotic disease investigations. The findings indicate that ribotyping has been widely applied for epidemiological investigations, source tracking, and characterization of foodborne and zoonotic pathogens. These approaches have contributed to understanding bacterial diversity and monitoring antibiotic resistance patterns in animal populations and related food products. However, compared with high‐resolution molecular techniques such as whole genome sequencing (WGS), ribotyping demonstrates lower discriminatory power and limited resolution for fine‐scale epidemiological analysis. Despite these limitations, ribotyping remains a useful, accessible, and cost‐effective tool in certain laboratory and surveillance settings, particularly where advanced genomic technologies are not readily available. Overall, integrating ribotyping with newer genomic approaches can enhance the monitoring and control of infectious bacteria, thereby supporting animal health, food safety, and public health outcomes.

  • Open Access

    Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside

    byĀ Majid Taati Moghadam, Samane Mohebi, Raheleh Sheikhi, Meysam Hasannejad‐Bibalan, Shahla Shahbazi, Shadman Nemati

    The rapid global spread of antibiotic‐resistant bacteria presents a growing public health crisis, threatening the efficacy of existing antimicrobial treatments. As traditional antibiotics become increasingly ineffective, alternative therapies such as bacteriophages and endolysins have gained renewed scientific and clinical interest. These biological agents, naturally derived from bacteriophage life cycles, exhibit potent and selective antibacterial activity, especially against multidrug‐resistant pathogens. Despite decades of research, the clinical translation of phage and endolysin therapies remains limited due to regulatory, delivery, and stability challenges. This review provides a comprehensive overview of the mechanisms, advantages, and limitations of both bacteriophages and endolysins, including their structure, mode of action, and interaction with bacterial hosts. Particular attention is given to combination therapies, where synergistic effects have been observed–especially in biofilm‐associated infections. We also explore the latest findings from preclinical studies, clinical trials, and compassionate‐use cases, with an emphasis on genetically engineered and synthetic variants that enhance therapeutic potential. Furthermore, we discuss manufacturing challenges, regulatory barriers, and future directions such as personalized phage therapy and engineered endolysins. By synthesizing current knowledge, this review highlights the academic and translational significance of phage and endolysin‐based approaches in combating antibiotic‐resistant infections.


  • Open Access

    The relationship between gut microbiome and human diseases: mechanisms, predisposing factors and potential intervention

    byĀ Mohammad Shabani, Ali Ghoshehy, Amir Mohammad Mottaghi, Zahra Chegini, Azam Kerami, Aref Shariati, Majid Taati Moghadam

    The complex interrelation of gut microbiota with human health underlines the profound influence this microbial ecosystem has on mechanisms of disease and wellness. The gut microbiome profoundly impacts various human diseases, encompassing gastrointestinal disorders, metabolic disorders, neurological disorders, and immune-related diseases. Gastrointestinal disorders are closely linked to microbial imbalances in the gut. Metabolic disorders, including obesity and type 2 diabetes, are influenced by the gut microbiota’s role in energy regulation and glucose metabolism. Furthermore, the gut-brain axis highlights the correlation between gut microbiota and neurological conditions such as Alzheimer’s and Parkinson’s. Moreover, the gut microbiome assumes a pivotal function in regulating the immune system, whereby dysbiosis is implicated in developing immunological-related ailments, including allergies and autoimmune disorders. Predisposing factors, including diet, medicines, lifestyle, and environmental influences, are described as having an important role in the composition of the gut microbiome. By understanding these factors, we can get valuable insights into how to intervene to reduce the chances of a disease. Current interventions, including probiotics, prebiotics, fecal microbiota transplants, and lifestyle modification, show promise, but there are still challenges and unanswered questions in this evolving field that may lead to improvements. This review interrelates the complicated gut microbiome with various human diseases, mechanisms, predisposing factors, and potential interventions.


  • Open Access

    A Focused Review on Commercially Available Automated Systems for Antibiotic Susceptibility Testing

    byĀ Qumars Ghavami, Haider Abd Ulhai Nasser, Seyedeh Shadi Vaziri, Majid Taati Moghadam

    The battle against antibiotic resistance demands innovative solutions for efficient and accurate antibiotic susceptibility testing (AST). Traditional methods, though reliable, are often time‐consuming and labor‐intensive, limiting their ability to provide timely results in clinical settings. In response, automated systems have emerged as a revolutionary tool, offering rapid, precise, and comprehensive AST processes. The purpose of this review article was to provide a comprehensive guide on automated methods for AST, exploring their principles, advantages over traditional techniques, and implications for clinical practice. By examining recent advancements in this field, we highlight how these innovative approaches can revolutionize our ability to detect antibiotic resistance swiftly and accurately, ultimately improving patient outcomes and combating the growing threat of antimicrobial resistance. The findings from the collected studies indicate that employing various automated techniques for assessing antibiotic resistance facilitates the identification of resistance and allows for precise detection of different pathogens from infectious samples. These automated methods have the potential to decrease hospital stay duration and future treatment costs. Moreover, by accurately detecting resistance more quickly, they can lead to more targeted treatments, ultimately reducing patient mortality rates.


  • Open Access

    Genetically engineered phages and engineered phage-derived enzymes to destroy biofilms of antibiotics resistance bacteria

    byĀ Fatemeh Eghbalpoor, Mahdieh Gorji, Maryam Zamani Alavigeh, Majid Taati Moghadam